Side-by-side comparison of AI visibility scores, market position, and capabilities
Bengaluru 30-minute medicine delivery with digital health records and chronic care management; YC W20 $3.1M at ₹10.7Cr revenue with 36% CAGR competing with PharmEasy and 1mg for India pharmacy delivery.
Farmako Healthcare is a Bengaluru-based healthtech platform — backed by Y Combinator (W20) and HOF Capital with $3.1 million raised including a $1.6 million round in August 2024 and a pre-Series A in June 2025 — providing ultra-fast medicine delivery (30-minute delivery within service areas), digital health records management, and personalized health insights for patients managing chronic conditions and routine pharmacy needs in Indian metros. Founded in 2019 and generating ₹10.7 crore (approximately $1.3 million USD) in annual revenue as of March 2024 with 36% revenue CAGR and a 63-person team, Farmako serves the medication adherence and pharmacy access market in India's urban health ecosystem.
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.